Can the Q-TWiST method provide information on patients' preferences without collecting preference data from the patients? In reply

被引：0
|
作者：
Zee, B [1 ]
James, K [1 ]
Pater, J [1 ]
机构：
[1] NCI, Clin Trials Grp, Kingston, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 1998年 / 16卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3718 / 3718
页数：1
相关论文
共 44 条
  • [21] Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Quizartinib Vs Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML)
    Cortes, Jorge E.
    Ganguly, Siddhartha
    Khaled, Samer K.
    Kramer, Alwin
    Levis, Mark J.
    Martinelli, Giovanni
    Perl, Alexander E.
    Russell, Nigel H.
    Botteman, Marc
    Shah, Ruchit
    Luo, Linlin
    Shun, Zhenming
    Ray, Saurabh
    [J]. BLOOD, 2019, 134
  • [22] QUALITY ADJUSTED TIME WITHOUT SYMPTOMS OF DISEASE PROGRESSION OR TOXICITY (Q-TWIST) OF NIVOLUMAB PLUS IPILIMUMAB (NIVO plus IPI) VS SUNITINIB (SUN) AMONG UNTREATED ADVANCED RENAL CELL CARCINOMA (ARCC) PATIENTS (PATIENTS) WITH INTERMEDIATE OR POOR PROGNOSTIC RISK
    Shah, R.
    Botteman, M.
    Kwon, Y.
    Gooden, K. M.
    Cella, D.
    Motzer, R.
    [J]. VALUE IN HEALTH, 2019, 22 : S106 - S106
  • [23] Quality of Time Spent Without Symptoms of Disease or Toxicity of Treatment (Q-TWIST) in Diabetic Patients with CLI and Digital Gangrene. Does Primary TMA After Revascularization Offer Superior Outcome? A 12-Year Experience
    Elsherif, Mohammed
    Tawfick, Wael
    Sultan, Sherif
    [J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2016, 185 : S429 - S429
  • [24] Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis
    McDermott, David F.
    Shah, Ruchit
    Gupte-Singh, Komal
    Sabater, Javier
    Luo, Linlin
    Botteman, Marc
    Rao, Sumati
    Regan, Meredith M.
    Atkins, Michael
    [J]. QUALITY OF LIFE RESEARCH, 2019, 28 (01) : 109 - 119
  • [25] Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis
    David F. McDermott
    Ruchit Shah
    Komal Gupte-Singh
    Javier Sabater
    Linlin Luo
    Marc Botteman
    Sumati Rao
    Meredith M. Regan
    Michael Atkins
    [J]. Quality of Life Research, 2019, 28 : 109 - 119
  • [26] NON-INVASIVE DATA PROVIDE INDEPENDENT PROGNOSTIC INFORMATION IN PATIENTS WITH CHEST PAIN WITHOUT PREVIOUS MYOCARDIAL-INFARCTION - FINDINGS IN MALE-PATIENTS WHO HAVE HAD CARDIAC-CATHETERIZATION
    LUWAERT, RJ
    MELIN, JA
    BROHET, CR
    ROUSSEAU, MF
    PONLOT, R
    DHONDT, AM
    VANBUTSELE, R
    ROBERT, A
    DETRY, JMR
    [J]. EUROPEAN HEART JOURNAL, 1988, 9 (04) : 418 - 426
  • [27] Estimated net benefit of avelumab (AVE) plus best supportive care (BSC) vs BSC alone for patients (pts) with advanced urothelial carcinoma (aUC) using a quality-adjusted time without cancer symptoms or toxicity (Q-TWiST) analysis.
    Powles, Thomas
    Cislo, Paul
    Kirker, Melissa
    Chang, Jane
    Gharibian, Norbek
    Thompson, Allison
    Costa, Nuno
    Grivas, Petros
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of patients in CheckMate 649: Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC)
    Sugarman, Ryan
    Botteman, Marc
    Rusibamayila, Nifasha
    Nguyen, Hiep
    Lin, Daniel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [29] A QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS OF DISEASE AND TOXICITY (Q-TWIST) ANALYSIS COMPARING NIVOLUMAB AND THERAPY OF INVESTIGATOR'S CHOICE (IC) IN PATIENTS WITH RECURRENT OR METASTATIC (R/M) PLATINUM-REFRACTORY SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) (CHECKMATE 141)
    Simpson, S.
    Cocks, K.
    Contente, M.
    DeRosa, M.
    Taylor, F.
    Shaw, J. W.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A450 - A450
  • [30] EFFICACY AND SAFETY OF THE USE OF LENALIDOMIDE IN PATIENTS SUFFERING FROM MYELODYSPLASTIC SYNDROME WITHOUT DELETION OF 5Q DATA OF THE SPANISH REGISTRY OF SMD
    Sanchez Garcia, J.
    Diez Campelo, M.
    Ramos, F.
    Andreu, R.
    Santiago, O.
    Josefina, S.
    Javier, C.
    Sanz, G.
    [J]. HAEMATOLOGICA, 2015, 100 : 22 - 22
12345